These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27222674)

  • 1. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.
    Yuasa S; Sato K; Takai M; Ishikawa M; Umezawa S; Kubota A; Maeda H; Kanamori A; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Jun; 8(6):461-71. PubMed ID: 27222674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.
    Takai M; Ishikawa M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2019 May; 11(5):311-320. PubMed ID: 31019624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.
    Takeda H; Sasai N; Ito S; Obana M; Takuma T; Takai M; Kaneshige H; Machimura H; Kanamori A; Nakajima K; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):130-40. PubMed ID: 26767082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study.
    Ishikawa M; Takai M; Maeda H; Kanamori A; Kubota A; Amemiya H; Iizuka T; Iemitsu K; Iwasaki T; Uehara G; Umezawa S; Obana M; Kaneshige H; Kaneshiro M; Kawata T; Sasai N; Saito T; Takuma T; Takeda H; Tanaka K; Tsurui N; Nakajima S; Hoshino K; Honda S; Machimura H; Matoba K; Minagawa F; Minami N; Miyairi Y; Mokubo A; Motomiya T; Waseda M; Miyakawa M; Naka Y; Terauchi Y; Tanaka Y; Matsuba I
    J Clin Med Res; 2015 Aug; 7(8):607-12. PubMed ID: 26124906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer.
    Kanamori A; Matsuba I
    J Clin Med Res; 2013 Jun; 5(3):217-21. PubMed ID: 23671547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
    Katsuno T; Ikeda H; Namba M
    Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.
    Yanai H; Adachi H; Hamasaki H; Masui Y; Yoshikawa R; Moriyama S; Mishima S; Sako A
    J Clin Med Res; 2012 Aug; 4(4):251-8. PubMed ID: 22870172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
    da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
    Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
    Kubota A; Maeda H; Kanamori A; Matoba K; Jin Y; Minagawa F; Obana M; Iemitsu K; Ito S; Amamiya H; Kaneshiro M; Takai M; Kaneshige H; Hoshino K; Ishikawa M; Minami N; Takuma T; Sasai N; Aoyagi S; Kawata T; Mokubo A; Takeda H; Honda S; Machimura H; Motomiya T; Waseda M; Naka Y; Tanaka Y; Terauchi Y; Matsuba I
    J Diabetes Investig; 2012 Dec; 3(6):503-9. PubMed ID: 24843615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.
    Kojima Y; Kaga H; Hayashi S; Kitazawa T; Iimura Y; Ohno M; Yoshitsugu M; Fujiwara M; Hiyoshi T
    World J Diabetes; 2013 Feb; 4(1):8-13. PubMed ID: 23493856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus.
    Mori H; Okada Y; Arao T; Tanaka Y
    J Diabetes Investig; 2014 May; 5(3):313-9. PubMed ID: 24843780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
    Ogawa S; Ishiki M; Nako K; Okamura M; Senda M; Mori T; Ito S
    Tohoku J Exp Med; 2011 Feb; 223(2):133-5. PubMed ID: 21304217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides.
    Tanaka T; Goto H; Araki R; Yamamoto M; Tanaka T; Fujiwara R; Murata K
    J Diabetes Investig; 2014 Mar; 5(2):199-205. PubMed ID: 24843761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.
    Imai K; Murayama H; Hirose T
    Diabetes Ther; 2018 Oct; 9(5):1869-1881. PubMed ID: 30058059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes.
    Tajiri Y; Kawano S; Hirao S; Oshige T; Iwata S; Ono Y; Inada C; Akashi T; Hayashi H; Sato Y; Tojikubo M; Yamada K
    Int Sch Res Notices; 2014; 2014():639489. PubMed ID: 27419209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes.
    Takai M; Ishikawa M; Maeda H; Kubota A; Iemitsu K; Umezawa S; Kawata T; Takuma T; Takeda H; Tanaka K; Machimura H; Minagawa F; Mokubo A; Motomiya T; Kanamori A; Matsuba I
    J Clin Med Res; 2020 Mar; 12(3):200-208. PubMed ID: 32231757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.